Pink Sheets: Actelion Ltd (ALIOF) news stock charts
Actelion Ltd (ALIOF/ALIOF.PK) Penny Investment Summary:
Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart; and Zavesca, in-licensed from Oxford GlycoSciences, an oral medication indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders. In addition, it has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Actelion markets Tracleer in the United States, the European Union, Japan, Canada, Australia, and Switzerland. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.www.actelion.com
2,200 Employees
Founded in 1997
ACTELION LTD-REG (ALIOF:Pink OTC Markets Inc)
LAST $44.60 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of 8:10 PM 03/16/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ACTELION LTD-REG (ALIOF)
|
OPEN
$44.60
|
PREVIOUS CLOSE
$44.60
|
|
|
DAY HIGH
$44.60
|
DAY LOW
$44.60
|
|
|
52 WEEK HIGH
10/14/09 - $63.55
|
52 WEEK LOW
04/17/09 - $41.50
|
|
|
MARKET CAP
--
|
AVERAGE VOLUME 10 D
20.0
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
0.0
|
|
|
ALIOF Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ACTELION LTD-REG (ALIOF)
Actelion Ltd., Q3 2010 Earnings Call, Oct-21-2010
03/15/2010
Actelion Ltd., Q3 2010 Earnings Call, Oct-21-2010
Actelion Ltd. Receives FDA Response Letter for Zavesca (Miglustat) for the Treatment of Niemann-Pick Type C Disease
03/9/2010
Actelion Ltd. announced that the company has received a complete response letter from the U.S. Food and Drug Administration for its supplemental New Drug Application for Zavesca (miglustat) for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Picktype C (NP-C) disease, a rare, neurodegenerative genetic disorder. The FDA has requested additional preclinical and clinical information. Actelion will work diligently with the FDA to explore the best ways to address the points raised by the agency. Niemann-Pick type C diseaseNP-C disease is a rare, fatal, neurodegenerative, genetic condition, primarily affecting children and teenagers although the clinical manifestations can become apparent at any age. The symptoms are caused by the storage of some lipids -such as glycosphingolipids and cholesterol - within certain tissues in the body, including the brain. It is invariably progressive and most patients die within five to ten years of diagnosis; for the majority the disease is fatal during childhood. Neurological deterioration is the key feature of the disease, and can manifest itself as clumsy body movements, balance problems, slow and slurred speech, difficulty in swallowing, problems with eye movements and seizures. Intellectual decline is also common. In the final stages of the disease the child or young adult is frequently bedridden, has little muscle control and is intellectually impaired. Diagnosis of the disease can be difficult and may take years due to the rarity and heterogeneity of the condition.
Actelion Ltd. - Special/M&A Call
03/1/2010
Actelion Ltd. - Special/M&A Call
Actelion Ltd financial resources
ALIOF Competitors
| Company | Last | Change |
| Amicus Therapeutics Inc | $3.33 USD | +0.02 |
| BioMarin Pharmaceutical Inc | $22.60 USD | -0.07 |
| EPIX Pharmaceuticals Inc | $0.01 USD | 0.00 |
| Protalix BioTherapeutics Inc | $6.92 USD | -0.06 |
| United Therapeutics Corp | $56.98 USD | -0.13 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ALIOF | Industry Range |
| Price/Earnings | 18.3x |
|
| Price/Sales | 3.1x |
|
| Price/Book | 3.9x |
|
| Price/Cash Flow | 17.2x |
|
| TEV/Sales | 2.4x |
|
|
ALIOF |
||
|
ALIOF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Pink Sheets: More Recent Financial News About Actelion Ltd
Actelion shares slump as fibrosis drug fails study
2010-03-02 06:26:42
Keywords: Industries|Healthcare, ATLN, Actelion, ALIOF, Actelion Ltd Allschwil
Quote: AlertEmailPrintBy Steve Goldstein, MarketWatchLONDON (MarketWatch) -- Shares of Switzerland's Actelion lost nearly a fifth of their value after the company said a study showed a fibrosis drug didn't reduce the intensity or mortality from the disease.Actelion/quotes/comstock/06p!atln-otc(CH:ATLN45.90,-8.85,-16.16%)/quotes/comstock/11i!aliof(ALIOF41.80,-8.20,-16.40%) said a trial of bosetan, better known by the brand name Tracleer, didn't reduce morbidity and mortality for patients with idiopathic...Read article
Actelion fibrosis drug doesn't meet key endpoint
2010-03-01 03:27:57
Keywords: , ALIOF, Actelion Ltd Allschwil, ATLN, Actelion
Quote: TEL AVIV (MarketWatch) -- Actelion Ltd.,/quotes/comstock/11i!aliof(ALIOF50.00,-1.45,-2.82%)/quotes/comstock/06p!atln-otc(CH:ATLN54.75,-0.10,-0.19%) the Basel drugmaker, said on Monday that a clinical study of bosentan to treat idiopathic pulmonary fibrosis didn't meet its primary endpoint of reducing morbidity and mortality. The drug's safety profile was confirmed, but the results don't "support initiating regulatory proceedings," the company said. A150-patient exploratory study with Actelion's ...Read article
Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease - Information on the potential use of Zavesca(R) (miglustat) oral capsule to address the supply shortage of intravenous enzyme replacement therapy (imiglu
2010-01-25 04:03:48
Quote: ALLSCHWIL, SWITZERLAND--(Marketwire - 09/08/09) -
ALLSCHWIL/BASEL, SWITZERLAND - 8 September 2009 - Actelion Ltd
(SIX: ATLN) has distributed updated information to Healthcare
Professionals
who treat type 1 Gaucher patients in the United States regarding
the
potential use of Zavesca� (miglustat)to minimize the impact of
the
supply shortageof imiglucerase(produced andmarketed by
Genzyme
Corporation under the brand name Cerezyme�).Despitestrictsupplyconservationmeasurescurrently
being
im...Read article
Actelion: Insomnia drug progresses; more study set
2009-12-23 02:35:36
Keywords: , ALIOF, Actelion Ltd Allschwil, ATLN, Actelion
Quote: TEL AVIV (MarketWatch) -- Actelion Ltd.,/quotes/comstock/11i!aliof(ALIOF53.90,-1.80,-3.23%)/quotes/comstock/06p!atln-otc(CH:ATLN55.16,-1.39,-2.45%) the Allschwil, Switzerland, biopharmaceutical producer, reported on almorexant, in Phase III trials to treat insomnia. In the first Phase III study, conducted over two weeks, the drug met its primary endpoint; almorexant "demonstrated clinically meaningful effects on both sleep induction and sleep maintenance for patients suffering from primary insom...Read article
Actelion to pursue development of S1P1
2009-12-08 03:20:54
Quote: TEL AVIV (MarketWatch) -- Actelion Ltd.,/quotes/comstock/11i!aliof(ALIOF58.65,-1.24,-2.07%)/quotes/comstock/06p!atln-otc(CH:ATLN60.68,+0.01,+0.01%) the Allshwil, Switzerland, drugmaker, said on Tuesday that it would proceed with advanced clinical development for S1P1 as a treatment for psoriasis. This receptor agonist is already in clinical development for multiple sclerosis; a dose-finding study began recruiting MS patients in early October, Actelion said. Actelion said it would also study the ...Read article
Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease - Information on the potential use of Zavesca(R) (miglustat) oral capsule to address the supply shortage of intravenous enzyme replacement therapy (imiglu
2009-11-28 00:08:30
Quote: ALLSCHWIL, SWITZERLAND--(Marketwire - 09/08/09) -
ALLSCHWIL/BASEL, SWITZERLAND - 8 September 2009 - Actelion Ltd
(SIX: ATLN) has distributed updated information to Healthcare
Professionals
who treat type 1 Gaucher patients in the United States regarding
the
potential use of Zavesca� (miglustat)to minimize the impact of
the
supply shortageof imiglucerase(produced andmarketed by
Genzyme
Corporation under the brand name Cerezyme�).Despitestrictsupplyconservationmeasurescurrently
being
im...Read article
Would you like to leave a comment about Actelion Ltd ALIOF/ALIOF.PK
Find out what social network information about Actelion Ltd are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Actelion Ltd's Penny Stock there is more great penny stock and market information at Realpennies